Nautilus Biotechnology (NAUT) shares Q3 2025 results press release in 8-K

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Nautilus Biotechnology, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. The company reported these results through a press release dated October 28, 2025, which is included as Exhibit 99.1.

The report explains that this earnings information is being furnished, not filed, which affects how it is treated under securities laws and future regulatory filings. The filing itself does not detail the financial figures, directing readers instead to the accompanying press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

10/27/2025 - 05:48 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

NAUTILUS BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation)

001-39434

(Commission File Number)

98-1541723

(I.R.S. Employer

Identification No.)


2701 Eastlake Avenue East Seattle, Washington (Address of principal executive offices)						98102 (Zip code)

(206) 333-2001

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

NAUT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On October 28, 2025, Nautilus Biotechnology, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number						Description
99.1						Press Release dated October 28, 2025.
104						Cover page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 28, 2025


			NAUTILUS BIOTECHNOLOGY, INC.

			By:			/s/ Sujal Patel
			Name:			Sujal Patel
			Title:			Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Nautilus Biotechnology (NAUT) disclose in this 8-K filing?

Nautilus Biotechnology disclosed that it released a press release reporting financial results for the quarter ended September 30, 2025. The press release, dated October 28, 2025, is attached as Exhibit 99.1 and contains the detailed quarterly financial information.

Which period’s results does Nautilus Biotechnology (NAUT) address in this report?

The report addresses Nautilus Biotechnology’s financial results for the quarter ended September 30, 2025. These results are not detailed in the document itself but are provided in a separate press release furnished as Exhibit 99.1 to the current report.

How are the Nautilus Biotechnology (NAUT) earnings results treated under securities laws?

The earnings results are described as “furnished” rather than “filed” under Section 18 of the Securities Exchange Act of 1934. This distinction affects potential liability and incorporation of the information into other Securities Act or Exchange Act filings.

What exhibits are included with this Nautilus Biotechnology (NAUT) 8-K?

The filing includes Exhibit 99.1, a press release dated October 28, 2025 reporting quarterly financial results, and Exhibit 104, the cover page interactive data file embedded with the Inline XBRL document. Together, these exhibits supplement the brief narrative in the report.

Who signed the Nautilus Biotechnology (NAUT) 8-K for the October 28, 2025 report?

The 8-K was signed on behalf of Nautilus Biotechnology by Sujal Patel, Chief Executive Officer. His signature indicates the company’s authorization of the filing and its contents under the requirements of the Securities Exchange Act of 1934.